Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029200 | 0.87 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL19306009 | 0.84 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL23045052 | 0.84 | POLB (0.56) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL29643255 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL4228749 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL29528302 | 0.80 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL879229 | 0.80 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL10603640 | 0.80 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL9320197 | 0.79 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL10682779 | 0.79 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157742-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3768682-B1 | 2-({2H,3H-[1,4]DIOXINO[2,3-G]QUINOLIN-7-YL}SULFANYL)ACETAMIDE DERIVATIVES AS BCR-ABL KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ALLCRON PHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3768682-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | Allcron Pharma Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019182944-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | ALDH1A1 3210/4885SMN1; SMN2 4029/4885HTT 4491/4885 |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | ALDH1A1 3210/4885SMN1; SMN2 4029/4885HTT 4491/4885 |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | ALDH1A1 2686/4885SMN1; SMN2 4130/4885HTT 4434/4885 |
| US-12157742-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | ALDH1A1 2686/4885SMN1; SMN2 4130/4885HTT 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.